Poster

Long-term Safety, Tolerability, and Effectiveness of TV-46000—a Long-Acting Subcutaneous Antipsychotic (LASCA)—in Patients With Schizophrenia: A Phase 3, Randomized, Double-Blind Study (SHINE)

Abstract: Background: TV-46000 is a long-acting subcutaneous antipsychotic (LASCA) that combines risperidone and an innovative, copolymer-based drug delivery technology. In the RISE study...

08/20/2024

The SOLARIS Protocol: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial Assessing Safety and Efficacy of TV-44749 (Olanzapine for Extended-Release Injectable Suspension Use) in Adults With Schizophrenia

Abstract: Background: Among patients with schizophrenia, nonadherence to oral antipsychotics increases relapse risk. Adherence may be improved with long-acting injectable (LAI) antipsycho...

08/20/2024

Differences in Patient and Healthcare Professional Perspectives on the Key Impacts of Tardive Dyskinesia

Abstract: Background: Physical manifestations of tardive dyskinesia (TD) impact daily activities and present a substantial psychosocial burden.

08/20/2024

Dosing and Treatment Patterns of Deutetrabenazine When Initiated Using a 4-Week Patient Titration Kit: Interim Results of the START Study

Abstract: Background: Deutetrabenazine is a vesicular monoamine transporter type 2 inhibitor (VMAT2i) for treatment of adults with tardive dyskinesia (TD) and Huntington disease (HD)-rela...

08/20/2024

Drug-Drug Interactions With Vesicular Monoamine Transporter 2 Inhibitors: Population Estimate of Patients With Tardive Dyskinesia at Risk in Real-World Clinical Practice

Abstract: Background: Valbenazine and deutetrabenazine (vesicular monoamine transporter 2 inhibitors) are approved in the US for treatment of adults with tardive dyskinesia (TD). Valbenaz...

08/20/2024

Education to Improve Treatment-Resistant Depression Diagnosis in the Outpatient Behavioral Health Setting

Abstract: Treatment-resistant depression can be difficult to identify in the outpatient behavioral health setting due to a lack of clear diagnostic guidelines. The evidence-based improvem...

08/20/2024

EEG Topography and LORETA Tomography in Neuropathology and Treatment of Genetic Epilepsy

Abstract: Two patients with previous unsuccessful psychiatric treatment under went a neurophysiologic evaluation method that included EEG, QEEG and Loreta brain scans. Each patient's lab ...

08/20/2024

Fentanyl in Focus: Perspectives on Polysubstance Use in 2022

Abstract: Fentanyl positivity grew by nearly 150% nationally from 2019 to 2022 and is now the most frequently detected drug in those analyzed with substance use disorder. Furthermore, a r...

08/20/2024

A Clinical Conundrum: Cardiac Complications with Covid, Covid Vaccines, and Clozapine

Abstract: Background: We and others surmise that clozapine-induced myocarditis may be more common now that Covid-19 virus is among us. Clozapine, Covid, and the mRNA vaccine used to fight...

08/20/2024

A Single Arm Pivotal Trial to Assess the Efficacy of AKL-T01, a Novel Digital Intervention Designed to Improve Attention, in Adolescents Diagnosed with Attention Deficit Hyperactive Disorder (ADHD)

Abstract: STARS-ADHD-Adolescents was a multicenter, single-arm trial conducted at 14 US research sites to evaluate objective attention functioning and ADHD symptoms and impairments after ...

08/20/2024